Last $2.78 USD
Change Today +0.05 / 1.83%
Volume 107.1K
BTX On Other Exchanges
Symbol
Exchange
BTX is not on other exchanges.
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1301 Harbor Bay Parkway

Alameda, CA 94502

United States

Phone: 510-521-3390

Fax: 510-521-3389

BioTime, Inc., a biotechnology company, focuses on the emerging field of regenerative medicine. The company’s core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these ‘pluripotent’ stem cells are being developed by the company and its subsidiaries, each of which concentrates on different medical specialties, including neuroscience, oncology, orthopedics, and blood and vascular diseases. Regenerative medicine refers to a field of therapeutic product development that might allow all human cell and tissue types to be manufactured on an industrial scale. This new technology is made possible by the isolation of human embryonic stem (hES) cells and by the development of ‘induced pluripotent stem (iPS) cells’, which are created from regular cells of the human body using technology that allows adult cells to be ‘reprogrammed’ into cells with pluripotency like young hES-like cells. The company offers advanced human stem cell products and technology that could be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines that the company markets for both basic research and therapeutic product development. The company also markets human embryonic progenitor cells (hEPCs), which are called PureStem cell lines and developed using ACTCellerate technology. Stem Cells and Related Products for Regenerative Medicine Research The company consolidated the marketing of its existing research products and would be launching all new research products through ESI BIO. PureStem hEPCs The company acquired a license from Advanced Cell Technology to make and sell hEPCs using PureStem technology. This technology allows the rapid isolation of novel, highly purified progenitors, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The company offers 12 PureStem hEPC for purchase at http://esibio.com/products/, and http://bioreagents.lifemapsc.com. It anticipates adding additional PureStem hEPC and related ESpan growth media and differentiation kits over time. The company also begun the PureStem grant program. hES Cells Carrying Genetic Diseases The company plans to add to its product line novel muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. ESpan Cell Growth Media The company is marketing a line of cell-growth media products called ESpan. ESpy Cell Lines Additional new products that the company has targeted for launch in 2014 are ESpy cell lines. HyStem Hydrogels The company offers hydrogel cell culture matrix products for its customers to grow ESI BIO stem cells and differentiated derivatives in a three-dimentional matrix that mimics the environment that is found in a living animal. ReCyte Therapeutics—Treatment of Vascular Disorders ReCyte Therapeutics focuses on developing treatments for vascular disorders, including both age-related diseases and injuries. ReCyte Therapeutics has used the Cornell technology in combination with the PureStem technology to produce highly purified monoclonal embryonic vascular endothelial progenitor stem cells. The company owns 94.8% of the ReCyte Therapeutics. Customers The company’s major customers include Hospira, Inc. (Hospira); CJ CheilJedang Corp. (CJ); and Summit Pharmaceuticals International Corporation (Summit). Marketing Stem Cell Research Products: The company’s products for use in stem cell research are being offered through its ESI BIO division, and its marketing of existing sub-brands PureStem embryonic progenitors, HyStem hydrogel matrix products, ESI cGMP hES cell lines, and its new differentiation and stem cell reprogramming products is being consolidated under the new ESI BIO branding program and through its subsidiary LifeMap Sciences. Plasma Volume Expanders: Hexte

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTX:US $2.78 USD +0.05

BTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $0.06 USD +0.0009
Athersys Inc $2.73 USD +0.10
Cytori Therapeutics Inc $2.34 USD -0.01
Geron Corp $1.94 USD -0.03
NeoStem Inc $6.46 USD -0.20
View Industry Companies
 

Industry Analysis

BTX

Industry Average

Valuation BTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.6x
Price/Book 10.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIME INC, please visit www.biotimeinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.